Malignant Exocrine Pancreas Neoplasm — Trials

Malignant Exocrine Pancreas Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

930 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 360
Recruiting: 209
Ph III recruiting: 23
Growth YoY: +39.4%
Industry share: 40%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (136)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04712721	Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.	terminated	Early Phase 1	14	Novartis PharmaceuticalsINDUSTRY	2	Oct 10, 2025	clinicaltrials
NCT03890198	A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma	terminated	Early Phase 1	2	First Affiliated Hospital Xi'an Jiaotong UniversityOTHER	1	Jul 2, 2020